141 related articles for article (PubMed ID: 38137384)
1. Comparison of Targeted Biopsy and Combined Biopsy to Avoid Unnecessary Systematic Biopsy in Patients with PI-RADS 5 Lesions.
Yuan C; Li D; Wu J; Shen Q; Wang X; Xiao J; He Z; Zhou L; Li X; Liu Y; Zhao Z
Biomedicines; 2023 Nov; 11(12):. PubMed ID: 38137384
[TBL] [Abstract][Full Text] [Related]
2. Combining targeted and systematic prostate biopsy improves prostate cancer detection and correlation with the whole mount histopathology in biopsy naïve and previous negative biopsy patients.
Mischinger J; Schöllnast H; Zurl H; Geyer M; Fischereder K; Adelsmayr G; Igrec J; Fritz G; Merdzo-Hörmann M; Elstner J; Schmid J; Triebl A; Trimmel V; Reiter C; Steiner J; Rosenlechner D; Seles M; Pichler GP; Pichler M; Riedl J; Schöpfer-Schwab S; Strobl J; Hutterer GC; Zigeuner R; Pummer K; Augustin H; Ahyai S; Mannweiler S; Fuchsjäger M; Talakic E
Front Surg; 2022; 9():1013389. PubMed ID: 36277287
[TBL] [Abstract][Full Text] [Related]
3. [Diagnostic efficacy of prostate cancer using targeted biopsy with 6-core systematic biopsy for patients with PI-RADS 5].
Liu Y; Yuan CW; Wu JY; Shen Q; Xiao JX; Zhao Z; Wang XY; Li XS; He ZS; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 55(5):812-817. PubMed ID: 37807733
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer: diagnostic yield of modified transrectal ultrasound-guided twelve-core combined biopsy (targeted plus systematic biopsies) using prebiopsy magnetic resonance imaging.
Song C; Park SY
Abdom Radiol (NY); 2021 Oct; 46(10):4974-4983. PubMed ID: 34181040
[TBL] [Abstract][Full Text] [Related]
5. Current role of systematic biopsy in diagnosis of clinically significant prostate cancer in primary combined MRI-targeted biopsy: a high-volume single-center study.
Krausewitz P; Fostitsch D; Weiten R; Kluemper N; Stein J; Luetkens J; Kristiansen G; Ellinger J; Ritter M
World J Urol; 2023 Jan; 41(1):19-25. PubMed ID: 36477403
[TBL] [Abstract][Full Text] [Related]
6. Is There Still a Need for Repeated Systematic Biopsies in Patients with Previous Negative Biopsies in the Era of Magnetic Resonance Imaging-targeted Biopsies of the Prostate?
Exterkate L; Wegelin O; Barentsz JO; van der Leest MG; Kummer JA; Vreuls W; de Bruin PC; Bosch JLHR; van Melick HHE; Somford DM
Eur Urol Oncol; 2020 Apr; 3(2):216-223. PubMed ID: 31239236
[TBL] [Abstract][Full Text] [Related]
7. Positive Predictive Value of Prostate Imaging Reporting and Data System Version 2 for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis.
Mazzone E; Stabile A; Pellegrino F; Basile G; Cignoli D; Cirulli GO; Sorce G; Barletta F; Scuderi S; Bravi CA; Cucchiara V; Fossati N; Gandaglia G; Montorsi F; Briganti A
Eur Urol Oncol; 2021 Oct; 4(5):697-713. PubMed ID: 33358543
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic performance of transperineal prostate targeted biopsy alone according to the PI-RADS score based on bi-parametric magnetic resonance imaging.
Noh TI; Shim JS; Kang SH; Cheon J; Kang SG
Front Oncol; 2023; 13():1142022. PubMed ID: 37035173
[TBL] [Abstract][Full Text] [Related]
9. Systematic Biopsy of the Prostate can Be Omitted in Men with PI-RADS™ 5 and Prostate Specific Antigen Density Greater than 15.
Tafuri A; Iwata A; Shakir A; Iwata T; Gupta C; Sali A; Sugano D; Mahdi AS; Cacciamani GE; Kaneko M; Cai J; Ukimura O; Duddalwar V; Aron M; Gill IS; Palmer SL; Abreu AL
J Urol; 2021 Aug; 206(2):289-297. PubMed ID: 33818141
[TBL] [Abstract][Full Text] [Related]
10. Added Value of Prostate-specific Antigen Density in Selecting Prostate Biopsy Candidates Among Men with Elevated Prostate-specific Antigen and PI-RADS ≥3 Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate: A Systematic Assessment by PI-RADS Score.
Pellegrino F; Stabile A; Sorce G; Quarta L; Robesti D; Cannoletta D; Cirulli G; Barletta F; Scuderi S; Mazzone E; de Angelis M; Brembilla G; De Cobelli F; Salonia A; Montorsi F; Briganti A; Gandaglia G
Eur Urol Focus; 2023 Oct; ():. PubMed ID: 37865591
[TBL] [Abstract][Full Text] [Related]
11. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
[TBL] [Abstract][Full Text] [Related]
12. Comparison of prostate cancer detection rates between magnetic resonance imaging-targeted biopsy and transrectal ultrasound-guided biopsy according to Prostate Imaging Reporting and Data System in patients with PSA ≥4 ng/mL: a systematic review and meta-analysis.
Zhu K; Qin Z; Xue J; Miao C; Tian Y; Liu S; Zhu S; Gu Q; Hou C; Xu A; Yang J; Wang Z
Transl Androl Urol; 2019 Dec; 8(6):741-753. PubMed ID: 32038971
[TBL] [Abstract][Full Text] [Related]
13. [Clinical study of artificial intelligence-guided image fusion assisted transperineal prostate biopsy].
Hu J; Zhao XD; Zhou YL; Dong N; Ma MF; Chen YH; Sheng ZC; Dong J; He CQ; Xu S
Zhonghua Nan Ke Xue; 2023 Aug; 29(8):729-735. PubMed ID: 38619521
[TBL] [Abstract][Full Text] [Related]
14. Prospective PI-RADS v2.1 Atypical Benign Prostatic Hyperplasia Nodules With Marked Restricted Diffusion: Detection of Clinically Significant Prostate Cancer on Multiparametric MRI.
Costa DN; Jia L; Subramanian N; Xi Y; Rofsky NM; Recchimuzzi DZ; de Leon AD; Arraj P; Pedrosa I
AJR Am J Roentgenol; 2021 Aug; 217(2):395-403. PubMed ID: 32876473
[No Abstract] [Full Text] [Related]
15. Is it necessary for all patients with suspicious lesions undergo systematic biopsy in the era of MRI-TRUS fusion targeted biopsy?
Lv Z; Wang J; Wang M; Hou H; Song L; Li H; Wang X; Liu M
Int Braz J Urol; 2023; 49(3):359-371. PubMed ID: 37115180
[TBL] [Abstract][Full Text] [Related]
16. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
[TBL] [Abstract][Full Text] [Related]
17. Do patients with a PI-RADS 5 lesion identified on magnetic resonance imaging require systematic biopsy in addition to targeted biopsy?
Drobish JN; Bevill MD; Tracy CR; Sexton SM; Rajput M; Metz CM; Gellhaus PT
Urol Oncol; 2021 Apr; 39(4):235.e1-235.e4. PubMed ID: 33451935
[TBL] [Abstract][Full Text] [Related]
18. Systematic versus Targeted Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy among Men with Visible Lesions.
Patel HD; Koehne EL; Shea SM; Fang AM; Gorbonos A; Quek ML; Flanigan RC; Goldberg A; Rais-Bahrami S; Gupta GN
J Urol; 2022 Jan; 207(1):108-117. PubMed ID: 34428091
[TBL] [Abstract][Full Text] [Related]
19. Optimizing multiparametric magnetic resonance imaging-targeted biopsy and detection of clinically significant prostate cancer: the role of perilesional sampling.
Noujeim JP; Belahsen Y; Lefebvre Y; Lemort M; Deforche M; Sirtaine N; Martin R; Roumeguère T; Peltier A; Diamand R
Prostate Cancer Prostatic Dis; 2023 Sep; 26(3):575-580. PubMed ID: 36509930
[TBL] [Abstract][Full Text] [Related]
20. Is Additional Systematic Biopsy Necessary in All Initial Prostate Biopsy Patients With Abnormal MRI?
Cheng X; Xu J; Chen Y; Liu Z; Sun G; Yang L; Yao J; Zeng H; Song B
Front Oncol; 2021; 11():643051. PubMed ID: 33718240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
